Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:51:06.502Z.
Calculation as of: 2026-10-06T15:51:06.502Z.
Quote observation: 2026-10-06T15:49:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3328ed161ff00c537a80d7dceb604f662f1c22c4e65cb57a824bf36ce3bbbe60
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Corvus Pharmaceuticals, Inc.
Market Cap
$888.84M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$899.78M
EV/Sales Ratio
4.87x
TTM Avg
36.22x
3Y Avg
50.65x
5Y Avg
36.89x
Market Cap
$914.10M
EV/Sales Ratio
2.74x
TTM Avg
2.28x
3Y Avg
2.71x
5Y Avg
2.71x
Market Cap
$860.00M
EV/Sales Ratio
28.12x
TTM Avg
18.85x
3Y Avg
39.02x
5Y Avg
39.02x
Market Cap
$840.57M
EV/Sales Ratio
109.93x
TTM Avg
171.82x
3Y Avg
125.82x
5Y Avg
125.82x
Market Cap
$839.43M
EV/Sales Ratio
1.42x
TTM Avg
1.51x
3Y Avg
1.76x
5Y Avg
1.99x
Market Cap
$839.06M
EV/Sales Ratio
6.73x
TTM Avg
7.73x
3Y Avg
8.84x
5Y Avg
8.84x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $888.84M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $897.66M | 1.95x | 1.63x | 1.56x | 1.52x |
| Arbutus Biopharma Corp (ABUS)vs › | $899.78M | 4.87x | 36.22x | 50.65x | 36.89x |
| HealthStream, Inc. (HSTM)vs › | $914.10M | 2.74x | 2.28x | 2.71x | 2.71x |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $860.00M | 28.12x | 18.85x | 39.02x | 39.02x |
| CeriBell, Inc. (CBLL)vs › | $933.21M | 9.05x | 7.82x | 8.63x | 8.63x |
| Alumis Inc. (ALMS)vs › | $840.57M | 109.93x | 171.82x | 125.82x | 125.82x |
| QuidelOrtho Corporation (QDEL)vs › | $839.43M | 1.42x | 1.51x | 1.76x | 1.99x |
| Beta Bionics, Inc. (BBNX)vs › | $839.06M | 6.73x | 7.73x | 8.84x | 8.84x |
| Jade Biosciences, Inc. (JBIO)vs › | $833.18M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
